Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...

Novo Nordisk (NYSE: NVO) is under attack. Although the Denmark-based drugmaker is a pioneer and leader in the GLP-1 diabetes and weight loss drug markets, countless companies are trying to steal ...

Novo Nordisk predicts milder growth in 2025 after obesity star Wegovy doubles sales in Q4 Becker’s contributions to the campaign, meanwhile, include Type 2 diabetes-friendly twists on recipes ...

70. Shares of Novo Nordisk dropped Monday after the company reported that its next-generation obesity drug produced weight loss results in diabetes patients that fell short of investors ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

The Food and Drug Administration on Tuesday approved Novo Nordisk's Ozempic to treat chronic kidney disease in patients who also have Type 2 diabetes, expanding the use of the wildly popular ...

Oct 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... an adjunct to standard of care in 9,650 patients with type 2 diabetes and established cardiovascular disease and/or chronic ...

Novo Nordisk is among global pharma leaders in the diabetes and weight loss segments, with indicators of continued demand and sales growth. The firm's profit margin and expected EPS growth beats ...

About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg ... to phase out easy-to-use pens to deliver the diabetes medication. For Janice Barnes, one of ...

But what if Novo Nordisk could market a therapy that's even more effective than these two? Enter CagriSema, an investigational diabetes and obesity medicine the company is testing in phase 3 studies.